Dupixent drives a larger share of Sanofi's revenue, with atopic dermatitis, asthma, and CRSwNP as core indications. Learn ...
Morning Overview on MSN
New seasonal allergy treatments show promise, but no cure yet
A string of FDA approvals and late-stage clinical trials has expanded the toolkit for treating seasonal and environmental ...
HealthDay News — Individuals with one to three allergenic foods are able to introduce and continue eating allergenic foods at ...
Patients maintain their improvements off treatment, even after clearance of barzolvolimab, investigators report.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results